Serono spin­out grabs a $31M round for a pair of proof-of-con­cept Parkin­son’s tri­als

Near­ly 5 years ago, Prex­ton Ther­a­peu­tics was the first new biotech to be spun out of the wreck­age left be­hind af­ter Mer­ck KGaA de­cid­ed to shut­ter its big Serono op­er­a­tions in Gene­va and re­trench back in Darm­stadt. To­day, it’s tak­ing what it learned in a Phase I study of a new Parkin­son’s drug and ap­ply­ing it in a pair of mid-stage stud­ies that will put its the­o­ries on a new path­way to the test, fu­eled by a $31 mil­lion Se­ries B.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA